clinical trial

Tecovirimat showed no clinical benefit over placebo in treating mpox, with 79% vs 81% achieving resolution by day 29 in a major trial.

Arcutis reported 2025 revenue of $372.1M (123% growth) and raised 2026 guidance to $480-495M, driven by strong ZORYVE adoption and positive clinical data.

BVF Partners invests $52M in Disc Medicine despite FDA setbacks, betting on Phase 3 trial data and strong cash reserves through 2029.

Novo Nordisk cuts GLP-1 drug prices 50% to $675/month starting 2027 amid clinical setbacks and competitive pressure from rivals like Eli Lilly.

Artiva Biotherapeutics appoints veteran pharma executive Thad Huston as CFO with 30+ years experience, ahead of key FDA feedback and clinical data milestones.

Clene outlines 2026 regulatory milestones for ALS drug CNM-Au8, including FDA meeting, NDA submission, and Phase 3 trial, backed by $28 million funding.

Novo Nordisk's obesity drug UBT251 achieved 19.7% weight loss in Phase 2 trials for Chinese patients, offsetting recent setbacks from a failed competitor drug trial.

Bristol-Myers Squibb's Reblozyl achieved positive Phase 2 results for Alpha-Thalassemia, showing improved hemoglobin levels and reduced transfusion needs in patients.

REGENXBIO faces class action lawsuit alleging executives made false statements about RGX-111 gene therapy's efficacy and safety, seeking shareholder damages.

Novo Nordisk's CagriSema underperformed Eli Lilly's tirzepatide in weight-loss trials, delivering 20.2% versus 23.6% weight reduction, triggering stock declines amid intensifying obesity drug competition.

Novo Nordisk's stock fell 16% after CagriSema obesity drug failed to match Eli Lilly's tirzepatide in trial, showing weaker weight loss results and jeopardizing approval timeline.

Aligos presented clinical progress for hepatitis B and coronavirus treatments at CROI. Pevifoscorvir showed strong viral suppression, while ALG-097558 provided dosing data for impaired patients.

Inovio Pharmaceuticals faces FDA rejection of its lead drug candidate and mounting cash constraints, raising questions about the biotech firm's long-term viability without revenue-generating products.

Novo Nordisk shares plunged 13% after CagriSema obesity drug trial missed non-inferiority target versus Eli Lilly's tirzepatide, threatening competitive positioning.

Dyne Therapeutics will present five neuromuscular disease presentations at MDA 2026, showcasing cardiopulmonary data from DMD trial and Phase 3 design for myotonic dystrophy treatment.

Redmile Group adds $63M to Nurix stake despite stock decline, betting on promising BTK degrader clinical data and upcoming registrational trials.

Candel Therapeutics raises $100M via public share offering to fund commercialization of its prostate cancer gene therapy and ongoing lung cancer clinical trials.

Candel Therapeutics plans $100M stock offering to fund cancer treatment pipeline development, particularly for prostate and lung cancer therapies.

REGENXBIO faces securities class action alleging false statements about RGX-111 gene therapy program and clinical trial outcomes. Investors from February 2022-January 2026 may recover damages.

Long-acting HIV injectable therapy significantly outperforms daily pills in Phase 3 trial, showing lower failure rates and improved outcomes for patients with adherence challenges.